Recently, LumeNXT, Inc. has appointed Marc Beer as Chairman of the Board. LumeNXT, Inc. is a private company that focuses on development confidential surgical illumination line. Marc Beer has an extensive history that spans more than two and a half decades in the development and commercialization of biotech, pharmaceuticals, devices, and diagnostics. He now will hold a leadership role and add something new to his resume. Marc Beer spoke about his new role at LumeNXT, Inc. and says that he is proud to be working among such accomplished and dedicated people who are in the surgical field. He believes that the mission of LumeNXT, Inc. will increase the productivity of surgery with minimally invasive approaches. Different doctors who perform surgery that uses targeted illumination have found that precision and flexibility are enhanced compared to traditional techniques. LumeNXT, Inc. uses a heat reduction platform with advanced illumination. This is a low-cost option which leaves everyone happy. The co-founder of LumNXT, Inc., Paul Rhyne says that bringing Marc Beer in as a chairman is exciting because Marc has shown high levels of success with the startup companies he has worked with. Previously, Marc Beer has been the Founding Chairman and CEO of Renovia which is a company that helps women with pelvic floor disorders go through therapy. This is the first line of digital therapy of its kind. Before Marc Beer leads Renovia, he held various leadership roles in the biopharmaceutical field including responsibilities of commercial launches that addressed rare diseases on a universal scale. Additionally, Marc Beer was also a Founding Chairman of Minerva Neurosciences Inc. Minerva conducts clinical trials for late stages of numerous illnesses including schizophrenia, insomnia and major depressive disorder. Marc Beer doesn’t stop there with all of the impressive work in his tenure, he has been with companies in the biopharmaceutical field responsible for addressing rare diseases, global growth and acquisitions to mention a few. Marc Beer is seasoned in pharmaceuticals and is sure to bring LumeNXT, Inc. to new levels. With all of the experience that Marc Beer holds, it is quite possible that there can be some sort of groundbreaking technology in the works.
To be entrusted with a leadership position requires years of hard-earned respect and performance. No matter what industry we talk about, no company will hand out these awards for anything less than the absolute best out of someone. That said, perhaps the most important quality of all is having to be well-rounded. As a leader, you have to be able to take on more than the average professional. For that matter, you have to be able to also give guidance and advice at the same time. As we can see, this is why leadership positions are earned and not given. A great example of this can be seen with executive Marc Beer. Not only does mark have over 25 years of experience, but he has also proven to be a well-rounded professional with experience in the biotechnology and pharmaceutical industries. As impressive as that is, perhaps more impressive is the fact that he has played a crucial role in overseeing and leading a company that resulted in the rapid growth and organization of the company. Needless to say, he showed that he was a natural born leader. With this in mind, let’s take a closer look t the career of Marc Beer and how he managed to gain that prestigious leadership position at LumeNXT.
Chairman Of The Board
Without a doubt, a chairman of the board is the holder of the last words and decisions of the board of directors of a company. In other words, no one on a board of directors is entrusted with as much authority and power as the chairman. The reason this is an important distinction to make is that, yet again, we see first hand how respected Marc Beer is by his peers. As for LumeNXT, the company seems to be more than thrilled with the decision to make Marc Beer chairman. In fact, in an article on LumeNXT and Marc Beer’s new position, we get the sense that the company was more impressed with the amount of experience he brought with him. While they definitely didn’t overlook his other qualities, the development company prioritized Marc because of his proven success across more than two decades. In addition to that, it is very clear that both parties involved are more than happy with this outcome. From Marc Beer’s perspective, he states that e has never been more proud and dedicated to achieving success with LumeNXT. To be given such an important role must have encouraged him unlike any other accomplishment in his career thus far. Nonetheless, it is also made very clear that both Marc and LumeNXT are going to do whatever is in their power to achieve and surpass the goals they set for themselves. Learn more: https://renoviainc.com/
Dr. Clay Siegall is the CEO and founder of Seattle Genetics, a biotech firm that develops target drugs for cancer and other diseases that still have a high death rate. Since its beginnings in 1998, Dr. Siegall has helped Seattle Genetics become one of the premiere targeted therapy drug developers. To date, Seattle Genetics created the first FDA-approved antibody drug conjugate. They also have forged partnerships with drug manufacturers like Bayer, Pfizer and Genentech and produced at least 20 drugs that will soon be released.
It took ten years for Seattle Genetics to become profitable. In fact many times in 1999 and 2000, they came close to having to close their doors. In 2000, they decided to add some expert sales people to their staff. That coupled with the development of effective drugs led them to being a profitable company. Their first approved drug, ADCetris, approved for three applications will be exclusively Seattle Genetics for at least eleven years. Because the cost of developing drugs and getting them approved is so costly, Seattle Genetics has other sources of income. They also license technologies and partner with other drug companies manufacturing their production.
Dr. Siegall believes the traits of a successful entrepreneur are available for most people to access within themselves, if they have a great work ethic. Hard work is the difference between success or failure. The old standbys I.Q., what exclusive institution you graduated from or who you know are not the key to success. It’s applying a hard work ethic to everything you do.
Dr. Clay Siegall is not only the founder and CEO of Seattle Genetics; he also holds several other positions. He is an independent director for Ultragenyx Pharmaceutical Inc., a biopharmaceutical company that produces drugs that fight rare diseases. He also serves on the board of directors for Alder BioPharmaceuticals, Inc. and Mirna Therapeutics, Inc., privately-held biothechnology companies.
Dr. Siegall gained his work experience from Bristol-Myers Squibb Pharmaceutical Research Institute from 1991-1997 and National Cancer Institute, National Institutes of Health from 1998-1991. He was educated at the University of Maryland where he gained his B.S. degree in Zoology and at George Washington University where he obtained his Ph.D. in Genetics.